期刊
GENETIC EPIDEMIOLOGY
卷 47, 期 2, 页码 198-212出版社
WILEY
DOI: 10.1002/gepi.22514
关键词
CETP; drug target validation; effect modification; precision medicine
Genetic variants in drug targets can predict the long-term effect of drugs. In this study, we examined how sex and body mass index (BMI) influence the effect of genetically predicted lower CETP levels on biomarkers and cardiovascular outcomes. Our findings suggest that female sex and lower BMI are associated with beneficial lipid biomarker profiles when CETP concentrations are genetically reduced. However, these modifying effects did not extend to sex differences in cardiovascular outcomes. These results provide valuable insights into the clinical implications of CETP inhibitors and can support precision medicine applications.
Genetic variants in drug targets can be used to predict the long-term, on-target effect of drugs. Here, we extend this principle to assess how sex and body mass index may modify the effect of genetically predicted lower CETP levels on biomarkers and cardiovascular outcomes. We found sex and body mass index (BMI) to be modifiers of the association between genetically predicted lower CETP and lipid biomarkers in UK Biobank participants. Female sex and lower BMI were associated with higher high-density lipoprotein cholesterol and lower low-density lipoprotein cholesterol for the same genetically predicted reduction in CETP concentration. We found that sex also modulated the effect of genetically lower CETP on cholesterol efflux capacity in samples from the Montreal Heart Institute Biobank. However, these modifying effects did not extend to sex differences in cardiovascular outcomes in our data. Our results provide insight into the clinical effects of CETP inhibitors in the presence of effect modification based on genetic data. The approach can support precision medicine applications and help assess the external validity of clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据